Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices

Citation
Sd. Anderson et al., Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices, MED SCI SPT, 33(6), 2001, pp. 893-900
Citations number
33
Categorie Soggetti
Medical Research General Topics
Journal title
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
ISSN journal
01959131 → ACNP
Volume
33
Issue
6
Year of publication
2001
Pages
893 - 900
Database
ISI
SICI code
0195-9131(200106)33:6<893:LPFEAT>2.0.ZU;2-4
Abstract
Purpose: As new delivery devices and formulations are being introduced for drugs given by inhalation, there is a need to evaluate their equivalence wi th old preparations. One way to do this is to investigate their equivalence in protecting from exercise-induced asthma (EIA). Methods: We used a proto col for EIA to compare the protective effect of salbutamol delivered by the pressurised metered dose inhaler (pMDI) and the new Diskus dry powder devi ce. Twenty-seven asthmatic subjects with moderately severe EIA completed an exercise test on four separate days at two study centers. Exercise was per formed by cycling for 8 min while inhaling dry air (0% RH, 20-24 degreesC). The target workload in W was predicted as (53.76 x predicted FEV1) - 11.07 and 95% of this target was achieved at 4 min of exercise. This target was chosen in order to achieve ventilation between 50 and 60% of predicted maxi mum in the last 4 min. Results: There was no significant difference in the workload, ventilation, or heart rate achieved on the study days. The severi ty of EIA was measured as the % fall in FEV1. EIA severity was similar on t he placebo and control day and the coefficient of variation was 19.4%. The mean +/- SD % fall on the control, placebo, salbutamol by Diskus, and pMDI were 42.0% +/- 15, 39.4% +/- 17.6, 13.4% +/- 13.2, and 8.5% +/- 13.8, respe ctively. Salbutamol significantly inhibited the % fall in FEV1 after exerci se, and there was no difference between the preparations. Conclusion: The p rotocol described here is suitable for evaluating equivalence of salbutamol preparations in protecting against EIA and could be used to evaluate the p rotective effect of other medications.